Australia markets closed

Aeglea BioTherapeutics, Inc. (AGLE)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
11.86+0.19 (+1.63%)
At close: 04:00PM EDT
11.62 -0.24 (-2.02%)
After hours: 05:54PM EDT

Aeglea BioTherapeutics, Inc.

805 Las Cimas Parkway
Suite 100
Austin, TX 78746
United States
512 942 2935
https://www.aeglea.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees14

Key executives

NameTitlePayExercisedYear born
Mr. Jonathan D. Alspaugh M.B.A.Strategic Advisor568.55kN/A1983
Mr. James Paul Kastenmayer J.D., Ph.D.Consultant611.84kN/A1972
Mr. Scott L. BurrowsChief Financial OfficerN/AN/A1977
Dr. Cameron Turtle DPHIL, Ph.D.Chief Operating OfficerN/AN/A1990
Joey PerroneVP of Fin. & Investor RelationsN/AN/AN/A
Ms. Heidy Abreu King-Jones J.D., L.L.M.Chief Legal Officer & Corp. Sec.N/AN/A1983
Dr. Kelly Boothe Ph.D.Sr. Director of Corp. Communications & Investor RelationsN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Corporate governance

Aeglea BioTherapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.